Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q2 2025 Earnings Call Transcript
Operator: Greetings, and welcome to the Amphastar Pharmaceuticals' Second Quarter Earnings Call.
Amphastar Pharmaceuticals Inc. (AMPH)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Marshall Wace LLP Paul Marshall And Ian Wace | 848,685 | $19,485,809 | -18% | 0.02% |
| 2. | Millennium Management Israel Englander | 618,984 | $14,211,873 | -29% | 0.01% |
| 3. | Renaissance Technologies Jim Simons | 576,500 | $13,236,440 | +17% | 0.02% |
| 4. | 15,000,000 | $13,003,125 | -12% | 0.44% | |
| 5. | D E Shaw D. E. Shaw | 293,928 | $6,748,587 | +908% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.26 | 1,000 | $20,260.00 | 13,151 | 2020-08-14 | Filing | |
| $16.06 | 15,000 | $240,853.50 | 2,080,619 | 2018-05-16 | Filing | |
| $16.08 | 25,000 | $401,970.00 | 2,065,619 | 2018-05-15 | Filing | |
| $10.84 | 6,000 | $65,022.00 | 101,215 | 2014-08-25 | Filing | |
| $10.00 | 3,500 | $34,999.65 | 17,639 | 2014-08-19 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.83 | 500 | $10,415.75 | 77,031 | 2025-08-01 | Filing | |
| $23.47 | 500 | $11,733.95 | 77,531 | 2025-07-02 | Filing | |
| $25.67 | 500 | $12,835.05 | 72,909 | 2025-06-02 | Filing | |
| $24.08 | 500 | $12,041.45 | 73,409 | 2025-05-01 | Filing | |
| $28.38 | 500 | $14,190.25 | 73,909 | 2025-04-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,668,793 | $130,155,486 | 0% | |
| 2. | 92,674,000 | $80,415,369 | 0.49% | |
| 3. | 2,686,950 | $61,692,372 | 0% | |
| 4. | 2,034,930 | $46,721,993 | 0.04% | |
| 5. | 45,321,000 | $39,541,994 | 3.77% |
News See All
JPMorgan Downgrades Amphastar Pharmaceuticals (AMPH) to Neutral from Overweight, Brings PT Down to $30
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On May 12, JPMorgan downgraded Amphastar Pharmaceuticals, Inc.
13 Cheap Healthcare Stocks with Huge Upside Potential
On July 8, Kate Moore, Citi Wealth CIO, appeared on CNBC's 'Squawk Box' to talk about the recent rally in equities.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q1 2025 Earnings Call Transcript
Operator: Greetings and welcome to the Amphastar Pharmaceuticals First Quarter Earnings Call. At this time, all participants are in a listen-only mode.
10 Best Pharma Stocks to Buy for Long Term Growth
With big American pharmaceutical corporations always searching for medications in China, the US pharmaceutical industry is going through a unique trend never seen before.
12 Best Small Cap Pharma Stocks to Buy Now
Emily Field, Head of European Pharma Research at Barclays, spoke on CNBC on February 20 about the performance of obesity medications, the effects of US tariffs, and the dynamics of the pharmaceutical ...
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q4 2024 Earnings Call Transcript
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q4 2024 Earnings Call Transcript February 27, 2025Amphastar Pharmaceuticals, Inc. misses on earnings expectations.
12 Most Profitable Pharmaceutical Stocks Right Now
Healthcare, which includes numerous businesses that offer patient care, conduct research and development of novel treatments, and design, produce, and distribute diagnostic tools and tests, takes the ...
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q3 2024 Earnings Call Transcript
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q3 2024 Earnings Call Transcript November 6, 2024Amphastar Pharmaceuticals, Inc. misses on earnings expectations.
Piper Sandler's Top Technical Stock Picks: 20 Best Stocks
The start of October has seen another wild swing for markets. September's second half saw Wall Street rejoice as the Federal Reserve delivered its highly anticipated interest rate cut.